Sacituzumab Govitecan Continues to Prolong Survival in Patients With HR+/HER2– Breast Cancer
Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.
Rusfertide Leads to Controlled Hematocrit Levels and Fewer Phlebotomies in Polycythemia Vera
Following treatment with rusfertide, patients with polycythemia vera were able to significantly reduce their need for blood draws.
Frontline Panitumumab/mFOLFOX Elicits Longest Overall Survival To-Date in RAS Wild-Type Metastatic CRC
Phase 3 findings showed that panitumumab plus mFOLFOX significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer.
Frontline Bevacizumab Prolongs PFS, OS in Ovarian Clear Cell Carcinoma
Ovarian clear cell carcinoma is a rare histological type of epithelial ovarian cancer that is typically resistant to chemotherapy and is historically associated with poor prognosis for patients.
Patients With RAS Wild-Type Metastatic CRC Benefit from Panitumumab/mFOLFOX
Panitumumab with mFOLFOX demonstrated a clinical benefit for patients with left-sided RAS wild-type metastatic colorectal cancer in the PARADIGM trial (NCT02394795).
Niraparib, Abiraterone, and Prednisone Triplet Shows Efficacy, Safety in mCRPC With HRR Gene Alterations
The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Frontline Belzutifan Associated with Meaningful Clinical Activity in Treatment of VHL-Associated RCC
A phase 2 study reported clinical efficacy from the use of frontline belzutifan in patients with Von-Hippel Lindau (VHL).
Lifileucel Proves Efficacy in Pretreated Advanced Melanoma
Lifileucel produced durable responses in advanced melanoma that was previously treated an an immunotherapy agent.
Study Highlights Racial Disparities in Blood Cancer Diagnoses, Outcomes
Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes.
Recent Chemotherapy May Increase COVID-19 Mortality Risk for Patients With Thoracic Cancer
Chemotherapy administered within 3 months of a diagnosis of coronavirus disease 2019 (COVID-19) increased the risk of death in patients with thoracic cancer, according to findings from the global TERAVOLT Consortium registry.
For Patients with KRAS G12C-mutated NSCLC a New Inhibitor Was Granted a Fast Track Designation
The FDA has granted a fast track designation to the KRAS inhibitor AMG 510 for the treatment of patients who received prior treatment with KRAS G12C-mutated NSCLC.
Precision Medicine Is Possible for Pediatric Patients
According to the MATCH trial, about a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration.
EGFR-Targeted Activity Helps Differentiation Between TKIs in NSCLC
In a presentation during the 16th Annual Winter Lung Conference™, Gregory J. Riely, MD, PhD, discussed the spectrum of activity of many of these FDA-approved EGFR TKIs.
Pivotal Phase III Trial Initiated to Investigate Role of Cabozantinib in Advanced HCC
A large pivotal phase III trial has been initiated to evaluate the potential for the first-line combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in comparison with standard-of-care sorafenib (Nexavar) for patients with advanced hepatocellular carcinoma (HCC).
Earlier Adjuvant Chemotherapy Benefits Patients With TNBC
Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer (TNBC) is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure, according to findings from a retrospective study performed in Peru presented at the 2018 San Antonio Breast Cancer Symposium (SABCS).
Mobile Monitoring Technology Helps to Reduce Symptom Severity in HNC
Patients with head and neck cancer (HNC) who tracked their symptoms using the CYCORE (CYberinfrastructure for COmparative Effectiveness REsearch) system’s mobile and sensor technology experienced reduced symptom severity compared with those who received standard care, according to results of a large randomized trial.
Blood-Based Liquid Biopsy for Detecting Colorectal Cancers Has High Degree of Accuracy
Neoadjuvant Nivolumab Plus Ipilimumab Is Effective, But Toxic in Melanoma
Neoadjuvant treatment with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) demonstrated almost a tripling in objective response rate (ORR) compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events (AEs) for patients with high-risk resectable melanoma, according to a small study presented at the 2017 SITC Annual Meeting.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive Cranbury, NJ 08512